NRxp Pharma's Ketamine ANDA amendment reclassified as minor by FDA

NRx Pharmaceuticals announced the FDA Office of Generic Drugs has reclassified a major amendment to its ketamine ANDA as a minor amendment. This designation revision lowers the regulatory resource requirement and updates the goal date to November 10, 2026.